2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1 – small molecules by LCMS)

Author:

Fluhler Eric1,Hayes Roger2,Garofolo Fabio3,Dumont Isabelle3,Blaye Olivier Le4,Arnold Mark5,Bansal Surendra6,Verhaeghe Tom7,Wilson Amanda8,Stevenson Lauren9,Myler Heather5,Bauer Ronald10,Bergeron Annik3,Bustard Mark11,Cai Xiao-Yan12,Carbone Mary3,Cojocaru Laura13,Desai-Krieger Daksha14,Duggan Jeff15,Haidar Sam16,Ho Stacy17,Ingelse Benno18,Katori Noriko19,Lévesque Ann20,Lowes Steve21,Ma Mark22,Mettke Katalina23,Michon Josée24,Musuku Adrien25,Olah Timothy5,Patel Shefali25,Rose Mark22,Schultz Gary21,Smeraglia John26,Spooner Neil27,Stouffer Bruce5,Vazvaei Faye6,Wakelin-Smith Jason28,Wang Jian5,Welink Jan29,Whale Emma28,Woolf Eric15,Xue Li30,Yang Tong-Yuan25

Affiliation:

1. Pfizer, Pearl River, NY, USA

2. MPI Research, Mattawan, MI, USA

3. Algorithme Pharma Inc., 575 Armand-Frappier Blvd., Laval (Montreal) QC, H7V 4B3, Canada

4. France ANSM, St-Denis, France

5. Bristol-Myers Squibb, Princeton, NJ, USA

6. Roche Innovation Center, New York, NY, USA

7. Janssen Research & Development, Beerse, Belgium

8. AstraZeneca, Macclesfield, UK

9. Biogen Idec Inc., Cambridge, MA, USA

10. Austria AGES, Vienna, Austria

11. Health Canada, Ottawa, ON, Canada

12. Merck, Kenilworth, NJ, USA

13. Tandem Labs, West Trenton, NJ, USA

14. Forest Laboratories, Farmingdale, NY, USA

15. Merck Research Laboratories, West Point, PA, USA

16. Boehringer-Ingelheim, Ridgefield, CT, USA

17. Sanofi, Waltham, MA, USA

18. Merck, Oss, The Netherlands – Currently working at Quintiles

19. Japan MHLW-NIHS, Tokyo, Japan

20. inVentiv Health Clinical, Quebec City, QC, Canada

21. Quintiles, Ithaca, NY, USA

22. Amgen Inc., Thousand Oaks, CA, USA

23. Germany BfArM, Bonn, Germany

24. Pharmascience, Montreal, QC, Canada

25. Janssen Research & Development, Spring House, PA, USA

26. UCB Pharma, Braine-l'Alleud, Belgium

27. GlaxoSmithKline, Ware, UK

28. UK MHRA, London, UK

29. Dutch MEB, Utrecht, The Netherlands

30. Pfizer, Andover, MA, USA

Abstract

The 2014 8th Workshop on Recent Issues in Bioanalysis (8th WRIB), a 5-day full immersion in the evolving field of bioanalysis, took place in Universal City, California, USA. Close to 500 professionals from pharmaceutical and biopharmaceutical companies, contract research organizations and regulatory agencies worldwide convened to share, review, discuss and agree on approaches to address current issues of interest in bioanalysis. The topics covered included both small and large molecules, and involved LCMS, hybrid LBA/LCMS, LBA approaches and immunogenicity. From the prolific discussions held during the workshop, specific recommendations are presented in this 2014 White Paper. As with the previous years’ editions, this paper acts as a practical tool to help the bioanalytical community continue advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2014 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 1) covers the recommendations for small molecule bioanalysis using LCMS. Part 2 (Hybrid LBA/LCMS, Electronic Laboratory Notebook and Regulatory Agencies’ input) and Part 3 (Large molecules bioanalysis using LBA and Immunogenicity) will be published in the upcoming issues of Bioanalysis.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. 2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody (PART 1A – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis PART 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2024-05-02

2. 2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( PART 2 – Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies);Bioanalysis;2024-04-17

3. 2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 – Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization;Bioanalysis;2023-08

4. 2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A – Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2023-08

5. 2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach);Bioanalysis;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3